Enrico Martin

175 Emerging therapeutic targets Conclusion Non-cytotoxic systemic treatments have not yet demonstrated clinical efficacy for MPNST, but most promising are approaches targeting the PI3K/Akt/mTOR and VEGFR pathways, as well as utilization of oncolytic viruses. A combination of therapies will most likely be key to maximizing treatment effects. With several clinical trials now, at least in part, recruiting MPNST patients, new insights into therapeutic options for MPNST will likely result. 7